drugset / Trial / NCT00979589

Clopidogrel in High-risk Patients With Acute Non-disabling Cerebrovascular Events

NCT00979589

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to assess the effects of a 3-month regimen of clopidogrel initiated with a loading dose (LD) of 300 mg followed by 75 mg/day during the first 21days versus a 3-month regimen of ASA 75 mg/day alone on reducing the 3-month risk of any stroke (both ischemic and hemorrhagic, primary outcome) when initiated within 24 hours of symptom onset in high-risk patients with TIA or minor stroke.

Timeline

Start
2009-12
Primary completion
2012-03
Completion
2012-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 75 mg
Comparator Clopidogrel Small molecule 75 mg